SUSRF Stock Chart & Stats
$5.41
$0.00(0.00%)
At close: 4:00 PM EDT
$5.41
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$2.58 - $10.26
Previous CloseN/A
Volume40.00
Average Volume (3M)40.00
Market Cap
$285.84M
Enterprise Value$964.04
Total Cash (Recent Filing)$658.39M
Total Debt (Recent Filing)$2.86M
Price to Earnings (P/E)28.1
Beta0.29
Next Earnings
Nov 12, 2026EPS Estimate
0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.83
Shares Outstanding51,026,237
10 Day Avg. Volume120
30 Day Avg. Volume40
Financial Highlights & Ratios
PEG Ratio-0.50
Price to Book (P/B)0.39
Price to Sales (P/S)1.67
P/FCF Ratio24.35
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$4.73Price Target Upside-12.65% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.22
Revenue Forecast (FY)$104.60M
Bulls Say, Bears Say
Bulls Say
Strong Growth And Recurring License MomentumRapid license growth and rising mix support a more scalable revenue model than hardware alone. Broader adoption across robotics customers can deepen recurring content relationships and improve revenue quality over the next several quarters.
Margin Delivery And Operational ImprovementsAchieving the target margin while growing indicates operating discipline and potential scalability. Pricing, product mix, and lower sales and administrative cost ratios could help sustain profitability as simulator volumes and license activity expand.
Debt-free Balance Sheet And Positive Cash GenerationA debt-free balance sheet gives Surgical Science flexibility to fund production capacity, product development, and strategic initiatives without material financing pressure. Positive operating cash flow also supports resilience through uneven project timing.
Bears Say
Profitability And Growth Have Cooled From Prior PeaksThe longer-term slowdown in growth and margin compression indicate that recent performance has not fully preserved earlier economics. Sustained recovery depends on converting operational improvements and product expansion into durable earnings growth.
Structural Weakness In ChinaSupport for domestic Chinese manufacturers represents a structural competitive and market-access challenge rather than a temporary demand dip. It may limit regional growth, require additional investment, and reduce the contribution from an important healthcare market.
Lumpy Revenue And Execution VisibilityLong sales cycles, project-based development work, and uncertain customer-related revenue changes can make results difficult to forecast. This volatility may complicate capacity planning and create periods where reported growth and cash conversion diverge.
Surgical Science Sweden AB News
SUSRF FAQ
What was Surgical Science Sweden AB’s price range in the past 12 months?
Surgical Science Sweden AB lowest stock price was $2.58 and its highest was $10.26 in the past 12 months.
What is Surgical Science Sweden AB’s market cap?
Surgical Science Sweden AB’s market cap is $285.84M.
When is Surgical Science Sweden AB’s upcoming earnings report date?
Surgical Science Sweden AB’s upcoming earnings report date is Nov 12, 2026 which is in 70 days.
How were Surgical Science Sweden AB’s earnings last quarter?
Surgical Science Sweden AB released its earnings results on Aug 19, 2026. The company reported $0.043 earnings per share for the quarter, missing the consensus estimate of $0.049 by -$0.005.
Is Surgical Science Sweden AB overvalued?
According to Wall Street analysts Surgical Science Sweden AB’s price is currently Overvalued.
Does Surgical Science Sweden AB pay dividends?
Surgical Science Sweden AB does not currently pay dividends.
What is Surgical Science Sweden AB’s EPS estimate?
Surgical Science Sweden AB’s EPS estimate is 0.07.
How many shares outstanding does Surgical Science Sweden AB have?
Surgical Science Sweden AB has 51,026,237 shares outstanding.
What happened to Surgical Science Sweden AB’s price movement after its last earnings report?
Surgical Science Sweden AB reported an EPS of $0.043 in its last earnings report, missing expectations of $0.049. Following the earnings report the stock price went up 24.688%.
Which hedge fund is a major shareholder of Surgical Science Sweden AB?
Currently, no hedge funds are holding shares in SUSRF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Surgical Science Sweden AB
Surgical Science Sweden AB (publ) specializes in the creation and distribution of virtual reality (VR) simulation platforms designed for evidence-backed training in laparoscopic and endoscopic procedures. Among its key offerings is the LapSim training system, which includes LapSim ST, tailored for educating surgical technologists and assistants, as well as LapSim essence, a compact and readily deployable VR simulator. The company's product portfolio further extends to the EndoSim system, a dedicated endoscopy simulator for comprehensive medical training. It also features TeamSim, an innovative platform fostering inter-professional education by integrating surgical simulation with real-world team dynamics. Additionally, they provide the Simball Box, which delivers velocity feedback alongside instructional task videos demonstrating optimal techniques, alongside their well-known Simbionix and robotic surgery simulators. Established in 1999, Surgical Science AB maintains its headquarters in Gothenburg, Sweden.
SUSRF Stock 12 Month Forecast
Average Price Target
$4.73
▼(-12.65% Downside)
Technical Analysis
RaySearch Laboratories AB
―
Stille AB
―
OssDsign AB
―
FluoGuide A/S
―
Physitrack Limited
―
Ownership Overview
―
Insiders
<0.01% Mutual Funds
― Other Institutional Investors
99.92% Public Companies and
Individual Investors